

Applicants: Paul B. Fisher, et al.  
Serial No.: 09/648,310  
Filed : August 25, 2000  
Page 3

acid consists of the polynucleotide sequence shown in SEQ  
ID NO:2.

51. (New) The host cell of claim 10, wherein the host cell is a  
tumor cell.

52. (New) The host cell of claim 51, wherein the tumor cell is a  
nasopharyngeal tumor cell, a thyroid tumor cell, a  
central nervous system tumor cell, a melanoma cell, an  
epithelial tumor cell, a non-epithelial tumor cell, a  
blood tumor cell, a leukemia cell, a lymphoma cell, a  
neuroblastoma cell, a cervical cancer cell, a breast  
cancer cell, a lung cancer cell, a prostate cancer cell,  
a colon cancer cell or a glioblastoma multiforme cell.

53. (New) The composition of claim 30, wherein the composition is  
a pharmaceutical composition.

Please amend claims 9 and 30. A clean version of amended claims 9  
and 10 follows:

B2 9. (Amended) A vector comprising the nucleic acid of any one of  
claims 1, 44, 45, 46, 47, 48, 49 or 50.

B3 30. (Amended) A composition which comprises any one of the  
nucleic acids of claims 1, 44, 45, 46, 47, 48, 49  
or 50 and a carrier.

#### REMARKS

Claims 1, 9-10, 13-22, 26, 30, 32, 34, 36 and 40 are pending. The  
Examiner asserted that claims 1, 9-10, 13-22, 26, 30, 32, 34, 36

Applicants: Paul B. Fisher, et al.  
Serial No.: 09/648,310  
Filed : August 25, 2000  
Page 4

and 40 are subject to restriction and/or election requirement. New claims 44-53 have been added. Support for new claim 44 may be found in the specification, *inter alia*, on page 6 lines 12-16. Support for new claim 45 may be found in the specification, *inter alia*, on page 6, lines 16-18. Support for new claim 46 may be found in the specification, *inter alia*, on page 6, lines 18-20. Support for new claim 47 may be found in the specification, *inter alia*, on page 6, lines 20-22. Support for new claim 48 may be found in the specification, *inter alia*, on page 6, lines 23-24. Support for new claim 49 may be found in the specification, *inter alia*, on page 6, lines 25-26. Support for new claim 50 may be found in the specification, *inter alia*, on page 6, lines 26-28. Support for new claim 51 may be found in the specification, *inter alia*, on page 6, lines 30-33. Support for new claim 52 may be found in the specification, *inter alia*, on page 6, line 33 through page 7, line 3. Support for new claim 53 may be found in the specification, *inter alia*, on page 8, lines 29-31. Applicant maintains that new claims 44-53 raise no issue of new matter and respectfully request entry of this amendment. Upon entry of this amendment, claims 1, 9-10, 13-22, 26, 30, 32, 34, 36, 40 and 44-53 will be pending and under examination.

Pursuant to the requirements of 37 C.F.R. §1.212, applicants attach hereto as **Exhibit A**, an annotated version of amended claims 9 and 30 to show all changes relative to the previous version of those claims.

Please amend claims 9 and 30. An annotated version of amended claims 9 and 10 follows:

9. (Amended) A vector comprising the nucleic acid of any one of claims 1 ,44, 45, 46, 47, 48, 49 or 50 [to 8].
30. (Amended) A composition which comprises any one of the nucleic acids of claims 1 ,44, 45, 46, 47, 48, 49 or 50 [to 8] and a carrier.